BioSpace News Archive

Oryzon Genomics, S.A. reported financial results for the fourth quarter ended December 31, 2022 and provided an update on recent developments.

Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Sorrento Therapeutics, Inc. posted an update to its previously issued “Frequently Asked Questions” document under the “Investors” section of its website at www.sorrentotherapeutics.com regarding its recent dividend to Sorrento stockholders of shares of common stock of Scilex Holding Company previously held by Sorrento.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, announced that all of the prefunded warrants that were issued in its public offering that closed on January 11, 2023 have been exercised in full.

BridgeBio Pharma, Inc. announced that on February 13, 2023, the compensation committee of BridgeBio’s board of directors granted 11 new employees restricted stock units for an aggregate of 59,800 shares of the Company’s common stock.

NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy, for patients with traumatic spinal cord injuries, is pleased to announce the interim results of an internal, preclinical study of its ExoPTEN drug.

Jasper Therapeutics, Inc. announced new positive Phase 1 data on briquilimab in combination with fludarabine and low-dose irradiation conditioning in older adults with acute myeloid leukemia or myelodysplastic syndromes undergoing allogeneic hematopoietic cell transplant.

AtriCure, Inc., a leading innovator in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, announced that the company will be participating in the upcoming Oppenheimer 33rd Annual Healthcare Conference.

The board of directors of Abbott declared a quarterly common dividend of 51 cents per share.